Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

crizotinib

(krih-ZOH-tih-nib)
A drug used to treat certain types of ALK-positive inflammatory myofibroblastic tumors in adults and children aged 1 year and older, ALK-positive systemic anaplastic large cell lymphoma in young adults and children aged 1 year and older, and ALK-positive or ROS1-positive non-small cell lung cancer. It is also being studied in the treatment of other types of cancer. Crizotinib blocks certain proteins made by the ALK and ROS1 genes, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Xalkori.
Search NCI's Dictionary of Cancer Terms